v3.20.1

Critical accounting judgments and key sources of estimation uncertainty - IFRS 15 – Revenue recognition Gilead (Details) € in Millions | 12 Months Ended |
--- | --- | ---
Dec. 31, 2019 EUR (€) item | Jul. 14, 2019 EUR (€)
Critical accounting estimates and judgments |  |
Fair value gain warrant A & B as derivatives | € 12.9 |
Decrease of the deferred income warrant a & b as derivatives | (28.6) |
Decrease in revenue recognized in current period warrant a & b as derivatives | (0.5) |
Equity increase and future revenue reduction | 85.6 |
Revenue from contracts with customers related to glpg1690 | € 17.7 |
Drug discovery platform revenue period | 10 years |
Decrease in interest expenses | € (6.9) |
Decrease in revenue recognition | (11.8) |
Decrease in current and non-current deferred income | € (4.9) |
Gilead |  |
Critical accounting estimates and judgments |  |
Number of performance obligations exceeding one year | item | 2 |
Period recognized to consideration paid for the platform | 10 years |
Gilead | Derivative financial instrument |  |
Critical accounting estimates and judgments |  |
Offsetting short term financial asset (derivative) |  | € 85.6
Number of performance obligations exceeding one year | item | 3 |

X
- Definition Adjustments for increase (decrease) in deferred income due to change in fair value of derivatives. + References No definition available. + Details
Name: | glpg_AdjustmentsForIncreaseDecreaseInDeferredIncomeDueToChangeInFairValueOfDerivatives
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period over which the company can recognize the drug discovery platform revenue. + References No definition available. + Details
Name: | glpg_DrugDiscoveryPlatformRevenuePeriod
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of equity and future revenue. + References No definition available. + Details
Name: | glpg_EquityAndFutureRevenue
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in deferred income due to Filgotinib amendment. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInDeferredIncome
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of increase (decrease) in interest expense due to Filgotinib amendment. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInInterestExpenses
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of increase decrease in revenue recognized during the period. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInRevenueDueToChangeInFairValueOfDerivatives
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of increase (decrease) in interest expense due to Filgotinib amendment. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInRevenueRecognition
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of performance obligations over a period of more than one year. + References No definition available. + Details
Name: | glpg_NumberOfPerformanceObligation
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period recognized to consideration paid for platform. + References No definition available. + Details
Name: | glpg_PeriodRecognizedToConsiderationPaidForPlatform
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOffsettingOfFinancialAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 85 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_85&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_GainsOnChangeInFairValueOfDerivatives
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The gross amount of recognised financial assets that are subject either to offsetting or to an enforceable master netting arrangement or similar agreement. [Refer: Financial assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2019-01-01 -Paragraph 13C -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2019-en-r&anchor=para_13C_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 113 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_113_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_114&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_DerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |